Prothena Corporation PLC
NASDAQ:PRTA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Prothena Corporation PLC
Total Equity
Prothena Corporation PLC
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Prothena Corporation PLC
NASDAQ:PRTA
|
Total Equity
$280.5m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-2%
|
|
|
Alkermes Plc
NASDAQ:ALKS
|
Total Equity
$1.8B
|
CAGR 3-Years
20%
|
CAGR 5-Years
11%
|
CAGR 10-Years
3%
|
|
|
Amarin Corporation PLC
NASDAQ:AMRN
|
Total Equity
$459.3m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
M
|
Mural Oncology PLC
NASDAQ:MURA
|
Total Equity
$140.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Prothena Corporation PLC
Glance View
Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.
See Also
What is Prothena Corporation PLC's Total Equity?
Total Equity
280.5m
USD
Based on the financial report for Dec 31, 2025, Prothena Corporation PLC's Total Equity amounts to 280.5m USD.
What is Prothena Corporation PLC's Total Equity growth rate?
Total Equity CAGR 10Y
-2%
Over the last year, the Total Equity growth was -42%. The average annual Total Equity growth rates for Prothena Corporation PLC have been -23% over the past three years , 9% over the past five years , and -2% over the past ten years .
